Adlai Nortye Ltd.(ANL)Earnings, Financials & Key Ratios
ANL•NASDAQ
Price updated Jun 11, 2026
AboutAdlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Show more
- Revenue$0-100.0%
- EBITDA-$53M+18.8%
- Net Income-$52M+50.5%
- EPS (Diluted)-4.89+68.3%
- ROE-98.95%+25.1%
- ROIC-730.77%-180.7%
- Debt/Equity1.07+168.9%
- Interest Coverage-28.22+67.0%
ANL Key Insights
Adlai Nortye Ltd. (ANL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 56.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ANL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANL Price & Volume
Adlai Nortye Ltd. (ANL) stock price & volume — 10-year historical chart
Loading chart...
ANL Growth Metrics
Adlai Nortye Ltd. (ANL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM55.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM51.04%
Return on Capital
10 Years-71.95%
5 Years-71.95%
3 Years-94.18%
Last Year-103.79%
ANL Recent Earnings
Adlai Nortye Ltd. (ANL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (38%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
Apr 10, 2026EPS
$0.18
Est $0.10
-71.4%
Revenue
$5M
Est $10M
-47.0%
Q4 2025
Dec 29, 2025EPS
$0.18
Est $0.18
+0.0%
Revenue
—
Est $313,233
Q3 2025
Aug 7, 2025EPS
$0.18
Est $0.18
+0.0%
Revenue
—
Q2 2025
Apr 30, 2025EPS
$0.22
Est $0.53
+58.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 10, 2026 | $0.18vs $0.10-71.4% | $5Mvs $10M-47.0% |
| Q4 2025 | Dec 29, 2025 | $0.18vs $0.18+0.0% | —vs $313,233 |
| Q3 2025 | Aug 7, 2025 | $0.18vs $0.18+0.0% | — |
| Q2 2025 | Apr 30, 2025 | $0.22vs $0.53+58.5% | — |
Based on last 12 quarters of dataView full earnings history →
ANL Peer Comparison
Adlai Nortye Ltd. (ANL) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZLAB | 1.95B | 17.64 | -11.03 | 15.33% | -39.29% | -24.32% | 0.31 | |
 ZYME | 1.69B | 22.97 | -21.26 | 38.87% | -126.33% | -0.25% | 0.07 | |
 CAN | 209.7M | 0.33 | -0.73 | 96.69% | -39.68% | -60.72% | 0.13 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 RCUS | 2.35B | 23.30 | -7.08 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 141.17M | 3.39 | -997.06 | 10.37% | 52.16% | |||
 NKTR | 1.16B | 59.21 | -6.09 | -43.89% | -284.18% | -87% | 1.66 | |
 MGNX | 254.89M | 4.01 | -3.40 | 0.78% | -44.79% | -147.8% | 1.92 |
Compare ANL vs Peers
Adlai Nortye Ltd. (ANL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANL Income Statement
Adlai Nortye Ltd. (ANL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 45.73M | 0 | 5M | 0 | 6.49M |
Revenue Growth % | - | - | - | -100% | - | -100% | - |
Cost of Goods Sold | 1.48M | 1.51M | 0 | 2.04M | 0 | 1.87M | 0 |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | -1.48M▲ 0% | -1.51M▼ 1.9% | 45.73M▲ 3131.2% | -2.04M▼ 104.5% | 5M▲ 345.3% | -1.87M▼ 137.4% | 6.49M▲ 0% |
Gross Margin % | - | - | 100% | - | 100.09% | - | 100% |
Gross Profit Growth % | - | -1.94% | 3131.23% | -104.46% | 345.27% | -137.42% | - |
Operating Expenses | 17.64M | 24.59M | 54.37M | 58.91M | 72.55M | 53.02M | 68.58M |
OpEx % of Revenue | - | - | 118.91% | - | 1452.28% | - | - |
Selling, General & Admin | 4.3M | 5.56M | 12.45M | 13.04M | 15.29M | 8.09M | 14.78M |
SG&A % of Revenue | - | - | 27.23% | - | 306.05% | - | - |
Research & Development | 13.34M | 19.04M | 42.1M | 54.49M | 58.15M | 44.94M | 56.92M |
R&D % of Revenue | - | - | 92.08% | - | 1164.05% | - | - |
Other Operating Expenses | 0 | 0 | -183K | -8.62M | -890K | 0 | -1000K |
Operating Income | -19.12M▲ 0% | -26.1M▼ 36.5% | -8.65M▲ 66.9% | -67.27M▼ 678.0% | -67.55M▼ 0.4% | -54.9M▲ 18.7% | -64.67M▲ 0% |
Operating Margin % | - | - | -18.91% | - | -1352.2% | - | -996.44% |
Operating Income Growth % | - | -36.53% | 66.87% | -678.05% | -0.42% | 18.73% | - |
EBITDA | -17.64M | -24.59M | -6.82M | -66.32M | -65.33M | -53.02M | -63.57M |
EBITDA Margin % | - | - | -14.91% | - | -1307.72% | - | -979.51% |
EBITDA Growth % | - | -39.43% | 72.29% | -873.05% | 1.49% | 18.83% | 7.74% |
D&A (Non-Cash Add-back) | 1.48M | 1.51M | 1.83M | 951K | 2.22M | 1.87M | 1.1M |
EBIT | -17.36M | -61.48M | -55.41M | -58.36M | -103.44M | -49.95M | -64.67M |
Net Interest Income | -443.28K | -1.72M | -1.31M | 117K | -729K | -1.94M | 1.49M |
Interest Income | 22.86K | 24.05K | 32.04K | 550K | 61.95K | 0 | 1.49M |
Interest Expense | 466.14K | 1.75M | 1.34M | 433K | 791K | 1.94M | 0 |
Other Income/Expense | 1.29M | -37.28M | -48.03M | 8.48M | -36.68M | 3M | 11.25M |
Pretax Income | -17.83M▲ 0% | -63.38M▼ 255.5% | -56.68M▲ 10.6% | -58.79M▼ 3.7% | -104.23M▼ 77.3% | -51.9M▲ 50.2% | -53.42M▲ 0% |
Pretax Margin % | - | - | -123.95% | - | -2086.37% | - | -823.14% |
Income Tax | 0 | 0 | 0 | 0 | 643K | 0 | 643K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | -0.62% | 0% | -1.2% |
Net Income | -17.83M▲ 0% | -63.38M▼ 255.5% | -56.68M▲ 10.6% | -58.79M▼ 3.7% | -104.87M▼ 78.4% | -51.9M▲ 50.5% | -54.06M▲ 0% |
Net Margin % | - | - | -123.95% | - | -2099.25% | - | -833.05% |
Net Income Growth % | - | -255.46% | 10.57% | -3.73% | -78.38% | 50.52% | 55.92% |
Net Income (Continuing) | -17.83M | -63.38M | -56.68M | -58.79M | -104.87M | -51.9M | -54.06M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.10▲ 0% | -7.62▼ 262.9% | -6.66▲ 12.6% | -6.93▼ 4.1% | -15.42▼ 122.5% | -4.89▲ 68.3% | -6.21▲ 0% |
EPS Growth % | - | -262.86% | 12.6% | -4.05% | -122.51% | 68.29% | 51.04% |
EPS (Basic) | -2.10 | -7.62 | -6.66 | -6.93 | -15.42 | -4.89 | - |
Diluted Shares Outstanding | 8.48M | 8.48M | 8.48M | 8.48M | 6.8M | 10.64M | 8.71M |
Basic Shares Outstanding | 8.48M | 8.48M | 8.48M | 8.48M | 6.8M | 10.64M | 8.71M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
ANL Balance Sheet
Adlai Nortye Ltd. (ANL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 6.43M | 28.59M | 124.54M | 66.3M | 101.19M | 64.06M | 100.28M |
Cash & Short-Term Investments | 6.02M | 24.5M | 117.94M | 64.05M | 98.5M | 60.91M | 97.99M |
Cash Only | 6.02M | 24.21M | 64.13M | 42.76M | 91.49M | 60.9M | 97.98M |
Short-Term Investments | 0 | 241K | 53.81M | 21.29M | 7.01M | 7K | 7K |
Accounts Receivable | 91.59K | 394.05K | 1.93M | 346K | 359K | 1.17M | 2.29M |
Days Sales Outstanding | - | - | 15.41 | - | 26.23 | - | 37.32 |
Inventory | 0 | 0 | 0 | -3 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 324.45K | 2.82M | 0 | 3 | 0 | 0 | 0 |
Total Non-Current Assets | 4.37M | 8.15M | 7.14M | 6.29M | 28.99M | 7.21M | 7.4M |
Property, Plant & Equipment | 3.34M | 6.59M | 6.59M | 5.88M | 3.8M | 2.71M | 2.88M |
Fixed Asset Turnover | - | - | 6.94x | - | 1.31x | - | 1.94x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 11K | 97K | 89K | 63K | 40K | 51K |
Long-Term Investments | 81.25K | 0 | 0 | 0 | 24.85M | 4.16M | 58.09M |
Other Non-Current Assets | 947.36K | 1.48M | 455K | 327K | 282K | 304K | 273K |
Total Assets | 10.8M▲ 0% | 36.74M▲ 240.1% | 131.69M▲ 258.4% | 72.59M▼ 44.9% | 130.19M▲ 79.3% | 71.27M▼ 45.3% | 107.68M▲ 0% |
Asset Turnover | - | - | 0.35x | - | 0.04x | - | 0.05x |
Asset Growth % | - | 240.1% | 258.4% | -44.87% | 79.34% | -45.26% | 280.06% |
Total Current Liabilities | 20.32M | 87.99M | 17.5M | 312.65M | 50.32M | 45.36M | 54.31M |
Accounts Payable | 5.26M | 1.53M | 2.98M | 13.1M | 14.35M | 10.15M | 11M |
Days Payables Outstanding | 1.3K | 369.54 | - | 2.35K | - | 1.98K | - |
Short-Term Debt | 10.92M | 82.99M | 10.46M | 4.31M | 30.36M | 26.33M | 38.89M |
Deferred Revenue (Current) | 0 | 0 | 0 | 3.88M | 0 | 5M | 0 |
Other Current Liabilities | 4.14M | 3.47M | 0 | 290.11M | 1.08M | -3.06M | 637K |
Current Ratio | 0.32x | 0.32x | 7.12x | 0.21x | 2.01x | 1.41x | 1.85x |
Quick Ratio | 0.32x | 0.32x | 7.12x | 0.21x | 2.01x | 1.41x | 1.85x |
Cash Conversion Cycle | - | - | - | - | - | - | 37.32 |
Total Non-Current Liabilities | 59.86M | 80.31M | 299.62M | 1.24M | 469K | 425K | 0 |
Long-Term Debt | 634.25K | 81.43M | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 1.9M | 2.05M | 1.24M | 469K | 425K | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 59.22M | -1.12M | 297.56M | 0 | 0 | 0 | 0 |
Total Liabilities | 80.18M | 168.3M | 317.11M | 313.89M | 50.79M | 45.78M | 54.31M |
Total Debt | 11.95M | 10.98M | 13.35M | 6.54M | 31.55M | 27.23M | 38.89M |
Net Debt | 5.93M | -13.22M | -50.79M | -36.21M | -59.94M | -33.68M | -58.45M |
Debt / Equity | - | - | - | - | 0.40x | 1.07x | 0.73x |
Debt / EBITDA | - | - | - | - | - | - | -0.61x |
Net Debt / EBITDA | - | - | - | - | - | - | 0.92x |
Interest Coverage | -41.01x | -14.94x | -6.46x | -155.36x | -85.40x | -28.22x | - |
Total Equity | -69.38M▲ 0% | -131.56M▼ 89.6% | -185.43M▼ 40.9% | -241.29M▼ 30.1% | 79.4M▲ 132.9% | 25.48M▼ 67.9% | 53.37M▲ 0% |
Equity Growth % | - | -89.62% | -40.95% | -30.13% | 132.91% | -67.9% | 503.56% |
Book Value per Share | -8.18 | -15.51 | -21.87 | -28.45 | 11.67 | 2.39 | 6.13 |
Total Shareholders' Equity | -69.38M | -131.56M | -185.43M | -241.29M | 79.4M | 25.48M | 53.37M |
Common Stock | 2.44K | 2.6K | 4K | 4K | 11K | 11K | 11K |
Retained Earnings | -86.62M | -159.15M | -209.43M | -268.22M | -373.09M | -429.32M | -400.7M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 17.24M | 27.59M | -1M | 9.53M | -4.24M | -4.54M | -4.33M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANL Cash Flow Statement
Adlai Nortye Ltd. (ANL) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -14.92M | -34.59M | -3.03M | -43.22M | -56.65M | -51.82M | -66.7M |
Operating CF Margin % | - | - | -6.64% | - | -1134.03% | - | - |
Operating CF Growth % | - | -131.81% | 91.23% | -1324.62% | -31.07% | 8.53% | -296.43% |
Net Income | -17.83M | -63.38M | -56.68M | -58.79M | -104.87M | -51.87M | -54.06M |
Depreciation & Amortization | 1.48M | 1.54M | 1.83M | 2.04M | 2.22M | 1.87M | 2.04M |
Stock-Based Compensation | 0 | 2.27M | 3.39M | 6.08M | 4.33M | 2.45M | 1.94M |
Deferred Taxes | 0 | 0 | -67K | -1.04M | 0 | 0 | 0 |
Other Non-Cash Items | -1.59M | 36.28M | 48.25M | -6.76M | 35.54M | 1.27M | -9.44M |
Working Capital Changes | 3.02M | -11.31M | 250K | 15.25M | 6.12M | -5.54M | -7.18M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 481.92K | -3.86M | 600K | 10.12M | 1.25M | -4.2M | 0 |
Cash from Investing | -184.52K | -1.61M | -54.86M | 28.38M | -10.95M | 28.07M | -4.81M |
Capital Expenditures | -184.95K | -1.62M | -1.12M | -1.27M | -200K | -170K | -237K |
CapEx % of Revenue | - | - | 2.45% | - | 4% | - | 3.65% |
Acquisitions | 434 | 10.14K | -102K | -2K | 0 | -4.21M | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 134K | 569K | 53.6K | 734K | -4.57M |
Cash from Financing | 16.22M | 53.89M | 97.2M | -6.78M | 116.24M | -6.58M | 108.79M |
Debt Issued (Net) | 0 | -2.58M | 1.01M | -6.49M | 25.06M | -4.86M | 0 |
Equity Issued (Net) | 0 | -1000K | 1000K | 0 | 1000K | 152.08K | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 16.22M | 57.7M | -1.19M | -292K | -602K | -1.87M | 108.79M |
Net Change in Cash | 1.11M▲ 0% | 18.19M▲ 1542.2% | 39.87M▲ 119.2% | -21.37M▼ 153.6% | 48.73M▲ 328.0% | -30.59M▼ 162.8% | 37.95M▲ 0% |
Free Cash Flow | -15.11M▲ 0% | -36.22M▼ 139.7% | -4.15M▲ 88.5% | -44.49M▼ 971.0% | -56.85M▼ 27.8% | -51.99M▲ 8.6% | -66.94M▲ 0% |
FCF Margin % | - | - | -9.08% | - | -1138.03% | - | -1031.39% |
FCF Growth % | - | -139.7% | 88.53% | -971.04% | -27.78% | 8.55% | -71.88% |
FCF per Share | -1.78 | -4.27 | -0.49 | -5.25 | -8.36 | -4.89 | -7.69 |
FCF Conversion (FCF/Net Income) | 0.84x | 0.55x | 0.05x | 0.74x | 0.54x | 1.00x | 1.24x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANL Key Ratios
Adlai Nortye Ltd. (ANL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -132.07% | -98.95% | -101.3% |
| Return on Invested Capital (ROIC) | - | - | - | -260.36% | -730.77% | -745.15% |
| Gross Margin | - | 100% | - | 100.09% | - | 100% |
| Net Margin | - | -123.95% | - | -2099.25% | - | -833.05% |
| Debt / Equity | - | - | - | 0.40x | 1.07x | 0.73x |
| Interest Coverage | -14.94x | -6.46x | -155.36x | -85.40x | -28.22x | - |
| FCF Conversion | 0.55x | 0.05x | 0.74x | 0.54x | 1.00x | 1.24x |
| Revenue Growth | - | - | -100% | - | -100% | - |
Related:ANL Dividend History·ANL Revenue History·ANL Price History·ANL P/E History·ANL Financial Ratios·ANL Institutional Holders
ANL Frequently Asked Questions
Adlai Nortye Ltd. (ANL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Adlai Nortye Ltd. (ANL) reported $6.5M in revenue for fiscal year 2024.
Adlai Nortye Ltd. (ANL) saw revenue decline by 100.0% over the past year.
Adlai Nortye Ltd. (ANL) reported a net loss of $54.1M for fiscal year 2024.
Dividend & Returns
Adlai Nortye Ltd. (ANL) has a return on equity (ROE) of -99.0%. Negative ROE indicates the company is unprofitable.
Adlai Nortye Ltd. (ANL) had negative free cash flow of $66.9M in fiscal year 2024, likely due to heavy capital investments.